

Synthesis of Diacetoxy Acetal Derivatives of Santonin and their Enhancing Effects on HL-60 Leukemia Cell Differentiation

Seung Hyun Kim, Sun Young Chung, Tae Sung Kim¹, and Bo Gil Choi

College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 500-757, Korea and ¹School of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Korea

(Received October 17, 2005)

Several diacetoxy acetal analogues have been synthesized from santonin and assessed for their ability of inducing or enhancing the differentiation of human HL-60 leukemia cells. The compounds themselves had little effect on HL-60 cell differentiation. However, three analogues, **2a**, **3a**, and **5b**, synergistically enhanced 1,25-dihydroxyvitamin D₃ [1,25-(OH)₂D₃]-induced HL-60 cell differentiation when combined with 5 nM of dihydroxyvitamin D₃ [1,25-(OH)₂D₃], a well-known differentiation inducer. Especially, the compound **5b** profoundly enhanced the 1,25-(OH)₂D₃-induced HL-60 cell differentiation.

Key words: Diacetoxyacetal, Santonin, Leukemia cell differentiation, Dihydroxyvitamin D₃

INTRODUCTION

Leukemia is a cancer that originates in the bone marrow and develops when a leukocyte undergoes transformation into malignant cells. Leukemia cells can be induced to undergo terminal differentiation by a variety of chemical and biological agents, indicating that the malignant state is not irreversible process. Certain cancers may eventually be treated with agents that induce terminal differentiation, presumably with less morbidity than that produced by cytotoxic agents (Beere *et al.*, 1993).

Human promyelocytic leukemia HL-60 cell culture has been employed as an excellent model system for studying cellular differentiation *in vitro*. HL-60 cells are differentiated into monocytic lineage when treated with 1,25-dihydroxyvitamin D₃ [1,25-(OH)₂D₃] (Breitman *et al.*, 1980; Tanaka *et al.*, 1983). 1,25-(OH)₂D₃ is currently under investigation as differentiating agents in a variety of tumor types and seem especially suited for clinical applications. 1,25-(OH)₂D₃ is a human hormone with a known physiological function in the control of calcium homeostasis. Differentiation and apoptosis-inducing effects of 1,25-(OH)₂D₃ have been demonstrated in neoplastic cells established in culture from these and other tissues (Studzinski *et al.*,

1995), showing that under appropriate conditions, 1,25-(OH)₂D₃ can indeed control the growth of these cells. The well-known limitation to the therapeutic use of 1,25-(OH)₂D₃ is its hypercalcemic effect. When the hypercalcemia is sufficiently prolonged and severe, widespread calcifications take place in tissues. Current attempts to overcome this problem focus on the combination therapy with nonhypercalcemic concentrations of 1,25-(OH)₂D₃ and compounds that have different mechanisms of action, such as paclitaxel (Hershberger *et al.*, 2001), curcumin (Sokoloski *et al.*, 1997), and silibinin (Kang *et al.*, 2001).

Recently, several sesquiterpene lactones have received considerable attention in pharmacological research due to their potent anti-neoplastic and anti-inflammatory activity (Hehner *et al.*, 1999; Ohnishi *et al.*, 1997). Cytostatic and cytotoxic effects of sesquiterpenes against tumor cells have also been reported (Hall *et al.*, 1988; Ross *et al.*, 1999).

In this report, we synthesized some analogues of diacetoxy acetal (**1**) and investigated not only their biological effects on cellular differentiation in the human promyelocytic leukemia HL-60 cell culture system, but also the effects of combinations of santonin derivatives with 1,25-(OH)₂D₃ on HL-60 cell differentiation.

Correspondence to: Bo Gil Choi, Ph.D., College of Pharmacy, Chonnam National University, Gwangju 500-757, Korea.
Tel: 82-62-530-2926, Fax: 82-62-530-2911
E-mail: bgchoi@chonnam.ac.kr

MATERIALS AND METHODS

Chemistry

Melting points were determined on a Mel-temp II laboratory device and are uncorrected. Nuclear magnetic resonance (NMR) data for $^1\text{H-NMR}$ were taken on Varian UNITY *plus* 300 spectrometers and are reported in δ ppm downfield from tetramethylsilane (TMS). The following abbreviations are used: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublet. IR spectra (IR) were determined neat or KBr disks on the Jasco FT-IR instrument and are reported in reciprocal centimeters. Thin layer chromatography (TLC) was carried out using precoated plates with silica gel 60F 254 purchased from Merck.

Synthesis of santonin derivatives

(11S)-3,3-(Ethylenedioxy)eudesmano-6-acetate-13-ol (2)

A solution of (11S)-3,3-(ethylenedioxy)eudesmano-13,6-acetate (Simonovic *et al.*, 1963; Kato *et al.*, 1971) (**1**, 7 g, 119.58 mmol) in 5% methanolic KOH (40 mL) was stirred at room temperature for 5 min and then poured into water. The floating solid was extracted with ether. The ethereal solution was washed with water and sat. NaCl aqueous solution and dried over MgSO_4 . After removal of the solvent the residue was recrystallized from ether-*n*-hexane to give the compound **2** (4.04 g, 60.3%): m.p. 155-158°C (Kato *et al.*, 1971, m.p. 150-152°C); IR(KBr) cm^{-1} : 3539, 1720, 1256; $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.82 (3H, d, $J = 6.6$, $>\text{CH-CH}_3$), 0.85 (3H, d, $J = 6.9$, $>\text{CH-CH}_3$), 0.91 (3H, s, $-\text{C-CH}_3$), 2.02 (3H, s, COCH_3), 3.46 (2H, d, $J = 7.2$, CH_2OH), 3.94 (4H, m, $\text{OCH}_2\text{CH}_2\text{O}$), 4.97 (1H, dd, $J_1 = J_2 = 10.2$, CHOAc).

(11S)-3,3-(Ethylenedioxy)eudesmano-6-acetate-13-ethanoate (2a)

A solution of the hydroxy-monoacetate (**2**, 0.2 g, 0.6 mmol) in propionic anhydride (1.17 g, 9 mmol) and pyridine (5 mL) was heated at 100°C over night and extracted with large amounts of ether. The ethereal solution was washed with sat. NaHCO_3 , water, 2N-HCl, NaCl solution and dried over MgSO_4 . Removal of the solvent gave the compound **2a** (0.23 g, 96%): IR(KBr) cm^{-1} : 1735; $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.83 (3H, d, $J = 7.2$ Hz, $>\text{CH-CH}_3$), 0.87 (3H, d, $J = 6.9$ Hz, $>\text{CH-CH}_3$), 0.92 (3H, s, $-\text{C-CH}_3$), 1.14 (3H, dd, $J_1 = 7.2$ Hz, $J_2 = 7.8$ Hz, COCH_2CH_3), 2.01 (3H, s, COCH_3), 2.32 (2H, q, $J_1 = 7.5$, COCH_2CH_3), 3.95 (6H, m, $\text{OCH}_2\text{CH}_2\text{O}$, CH_2OCO), 4.95 (1H, dd, $J_1 = 10.05$, $J_2 = 10.2$, CHOAc).

(11S)-3,3-(Ethylenedioxy)eudesmano-6-acetate-13-benzoate (2b)

Compound **2b** was synthesized from the hydroxy-mono-

acetate (**2**) in benzoic anhydride and pyridine using method described for compound **2a** (yield 53.6%): m.p. 180-181°C; IR(KBr) cm^{-1} : 1714; $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.84 (3H, d, $J = 3.3$, $>\text{CH-CH}_3$), 0.93 (3H, s, $-\text{C-CH}_3$), 0.97 (3H, d, $J = 6.9$, $>\text{CH-CH}_3$), 2.02 (3H, s, COCH_3), 3.95 (4H, m, $\text{OCH}_2\text{CH}_2\text{O}$), 4.15 (2H, m, CH_2O), 5.00 (1H, dd, $J_1 = J_2 = 10.2$ Hz, CHOAc), 7.56(3H, m, arom), 8.02 (2H, m, arom).

(11S)-3,3-(Ethylenedioxy)eudesmano-6-acetate-13-chloroformate (3)

Phosgen solution (2 mL, 1.47 mmol) was added to a solution of **2** (0.5 g, 1.47 mmol) in dry toluene 1 mL at 0°C. The solution was gently shaken at 0°C for 30 min and at room temperature for 2 h. The solution was concentrated under reduced pressure at a temperature not exceeding 60°C and afforded 0.55 g (yield 93%) of brown oil: IR (KBr) cm^{-1} : 1776, 1730; $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.91 (3H, d, $J = 6.9$, $>\text{CH-CH}_3$), 0.93 (3H, d, $J = 7.2$, $>\text{CH-CH}_3$), 0.97 (3H, s, $-\text{C-CH}_3$), 2.08 (3H, s, COCH_3), 3.93 (4H, m, $\text{OCH}_2\text{CH}_2\text{O}$), 4.13 (2H, m, CH_2OCO), 5.07 (1H, dd, $J_1 = J_2 = 10.5$, CHOAc).

(11S)-3,3-(Ethylenedioxy)eudesmano-6-acetate-13-carbamate (3a)

A solution of the chloroformate (**3**, 0.9 mmol) was added to ammonia water (0.9 mL, 4.5 mmol) slowly and with vigorous stirring. The reaction mixture allowed elevating to RT for 2 h. After removal of the solvent the residue was purified by silica gel column chromatography (Hexane: EtOAc=5:1) to give white solid **3a** (0.27 g, 67.3%): m.p. 131-132°C; IR (neat) cm^{-1} : 3446, 3360, 1723; $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.83 (3H, d, $J = 6.6$, $>\text{CH-CH}_3$), 0.87 (3H, d, $J = 6.9$, $>\text{CH-CH}_3$), 0.92 (3H, s, $-\text{C-CH}_3$), 2.02 (3H, s, COCH_3), 3.94 (6H, m, $\text{OCH}_2\text{CH}_2\text{O}$, CH_2OC), 4.66 (2H, s, CONH_2), 4.95 (1H, dd, $J_1 = J_2 = 10.2$, CHOAc).

(11S)-3,3-(Ethylenedioxy)eudesmano-6-acetate-13-benzoyl-carbamate(3b)

Compound **3b** was synthesized from the chloroformate(**3**) and benzylamine using method described for compound **3a** (yield 35.97%, white oil): IR(KBr) cm^{-1} : 3348, 1726; $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.84 (3H, d, $J=3.3$, $>\text{CH-CH}_3$), 0.93 (3H, s, $-\text{C-CH}_3$), 0.97 (3H, d, $J=6.9$, $>\text{CH-CH}_3$), 2.02 (3H, s, COCH_3), 3.85-4.20 (6H, m, $\text{OCH}_2\text{CH}_2\text{O}$, CH_2O), 4.97 (1H, t, $J=10.2$, CHOAc), 7.43-8.05 (5H, m, arom).

(11S)-3,3-(Ethylenedithioxy)eudesmano-13,6 α -diol (4)

The compound **4** was synthesized according the literature (Shibata *et al.*, 1986) from the tetrahydrosantonin (yield 32.12%): m.p. 185-186°C (Shibata *et al.*, m.p. 184-186°C); IR (KBr) cm^{-1} : 3401, 2921; $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.86 (3H, s, CH_3), 1.35 (3H, d, $J = 6.6$, $>\text{CH-CH}_3$), 1.43 (3H, d, $J = 6.9$, $>\text{CH-CH}_3$), 3.21 (4H, m, $\text{SCH}_2\text{CH}_2\text{S}$),

3.50 (3H, m, CHOH, CH₂OH).

(11S)-3,3-(Ethylenedithioxy)eudesmano-13,6 α -diacetate (4a)

Compound **4a** was synthesized from the diol **4** and Ac₂O and pyridine using method described for compound **2a** (yield 49.5%): m.p. 104-105°C; IR(KBr) cm⁻¹: 1736, 1721; ¹H-NMR (300 MHz, CDCl₃): δ 0.87 (3H, d, $J = 6.9$, >CH-CH₃), 0.91 (3H, s, CH₃), 1.14 (3H, d, $J = 6.6$, >CH-CH₃), 2.03 (3H, s, COCH₃), 2.06 (3H, s, COCH₃), 3.20 (4H, m, SCH₂CH₂S), 3.89 (2H, dd, $J_1 = 3.3$, $J_2 = 4.2$, CH₂OAc), 4.92 (1H, dd, $J_1 = J_2 = 10.05$, CHOAc).

(11S)-3,3-(Propylenedioxy)eudesmano-13,6 α -lactone (5)

A mixture of TS (2 g, 7.99 mmol), neopentyl glycol (18.6 g, 178.58 mol) and *p*-toluenesulfonic acid (0.08 g, 0.42 mmol) in dry benzene was refluxed in a flask equipped with a Dean-Stark column for 3 h. Subsequently, the reaction mixture was cooled and washed with sodium bicarbonate solution. The benzene layer was separated and washed with saturated NaCl solution and dried over MgSO₄. The residue was purified by column chromatography (Hexane: EtOAc=8:1) to give compound **5** (1.52 g, 69.9%): m.p. 164-165°C; IR (KBr) cm⁻¹: 1769; ¹H-NMR (300 MHz, CDCl₃): δ 0.72 (3H, s, CH₃), 0.98 (3H, s, CH₃), 1.19 (3H, d, $J = 6.6$, CH₃), 1.23 (3H, d, $J = 6.6$, >CH-CH₃), 3.32 (2H, m, OCH₂C), 3.71 (3H, m, OCH₂C, CHO).

(11S)-3,3-(Propylenedioxy)eudesmano-13,6 α -diol (5a)

The lactone **5** (1.88 g, 5.59 mmol) dissolved in dry THF (5 mL) was added carefully under stirring to a mixture of lithium aluminum hydride (0.42 g, 11.17 mmol) and dry THF. The reaction mixture was stirred and refluxed for 3 h and then decomposed in the usual way with ethyl acetate and H₂O. The solvent was removed and residue was extracted with ether to obtain crystalline crude product. Crystallization from MeOH gave 1.47 g (yield 77.8%) of the diol m.p. 145-146°C; IR (KBr) cm⁻¹: 3378; ¹H-NMR (300 MHz, CDCl₃): δ 0.72 (3H, s, CH₃), 0.85 (3H, s, CH₃), 0.89 (3H, d, $J = 7.2$, >CH-CH₃), 1.18 (3H, s, CH₃), 1.33 (3H, d, $J = 6.6$, >CH-CH₃), 3.31 (2H, m, CH₂OC), 3.47(2H, m, CH₂OH), 3.58 (1H, dd, $J_1 = 6.0$, $J_2 = 10.8$, CHOH), 3.71 (2H, dd, $J_1 = 11.55$, $J_2 = 45.6$, CH₂OC).

(11S)-3,3-(Propylenedioxy)eudesmano-13,6 α -diacetate (5b)

Compound **5b** was synthesized from the diol **5** and Ac₂O and pyridine using method described for compound **2a** (yield 55.2%); IR (KBr) cm⁻¹: 1731; ¹H-NMR (300 MHz, CDCl₃): δ 0.72 (3H, s, CH₃), 0.87 (3H, d, $J = 6.9$, >CH-CH₃), 0.90 (3H, s, CH₃), 1.03 (3H, d, $J = 6.6$, >CH-CH₃), 1.18 (3H, s, CH₃), 2.03 (3H, s, COCH₃), 2.04 (3H, s, COCH₃),

3.32 (1H, d, $J = 11.7$, CH₂OC), 3.52 (1H, s, CH₂OC), 3.70 (2H, dd, $J_1 = 11.25$, $J_2 = 44.7$, CH₂OC), 3.90 (2H, m, CH₂OAc), 4.95 (1H, dd, $J_1 = 10.95$, $J_2 = 10.2$, CHOAc).

Biology

HL-60 cell line was obtained from the American Type Culture Collection (ATCC, Rockville, MD, U.S.A.) and maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (Gibco BRL, Grand Island, NY, U.S.A.). The synthetic compounds were dissolved in dimethylsulfoxide to make a stock solution of 100 mg/mL. The solutions were diluted at least 1000-fold in the growth medium, such that the final concentration of dimethylsulfoxide had no effect on the differentiation and proliferation of HL-60 cells.

Determination of cell differentiation

HL-60 cell differentiation was assessed by the nitroblue tetrazolium reduction assay as previously described (Collins *et al.*, 1979). This assay is based on the ability of phagocytic cells to produce superoxide upon stimulation with PMA. For this assay, 2 \times 10⁵ cells were harvested by centrifugation and incubated with an equal volume of 1% NBT dissolved in PBS containing 200 ng/mL of freshly diluted PMA at 37°C for 30 min in the dark. Cytopsin slides were prepared and were examined for blue-black nitroblue diformazan deposits, indicative of a PMA-stimulated respiratory burst. At least 200 cells were assessed for each experiment.


Statistical analysis

Student's *t*-test and one-way analysis of variance (ANOVA) followed by the Bonferroni method were used to determine the statistical significance of differences between values for various experimental and control groups. A *P* value of <0.05 was considered as significant.

RESULTS AND DISCUSSION

Chemistry

As shown in Scheme 1, the diacetoxyl acetal derivative (**1**) was readily synthesized from the santonin using the previous reported procedure (Ando *et al.*, 1987; Kato *et al.*, 1971). Partial hydrolysis of the compound **1** using 5% KOH gave monoacetoxyl acetal (**2**), which was esterified using propionic anhydride or benzoic anhydride and pyridine to give propionic ester (**2a**) and benzoic ester (**2b**). Monoacetoxyl acetal (**2**) was transformed to chloroformate (**3**), which was sequentially carbamylated using addition of NH₄OH to give the carbamate (**3a**), having NH₂ group instead of CH₃ group of diacetoxyl acetal (**1**). Dithioacetal (**4**), a sulfur analogue of the compound **2** was synthesized from thioketalization of tetrahydrosantonin



Scheme 1. Synthetic pathway of target compound

using ethane dithiol and toluenesulfonic acid, and sequentially its reduction by lithium aluminum hydride, and acetylation by Ac_2O and pyridine gave (11*S*)-3,3-(ethylenedithioxy)-eudesmano-13,6 α -diacetate (**4a**). Similarly diacetoxyl acetal using 2,2-dimethylpropane diol instead of ethylene glycol *via* acetalization, reduction by LiAlH_4 and acetylation was synthesized according to the method as described above.

Effect of the synthesized santonin derivatives on HL-60 cell differentiation

HL-60 cells were seeded at a density of 2×10^5 cells/mL, and the cells were treated with medium alone, or treated for 72 h with 20 $\mu\text{g}/\text{mL}$ of each of the diacetoxyl acetal analogues. As shown in Table I, the treatment with 20 $\mu\text{g}/\text{mL}$ of compound **1** induced HL-60 cell differentiation approximately by 30.9%, whereas the other derivatives had little or no effect on cell differentiation.

In order to whether or not the santonin derivatives enhance HL-60 cell differentiation when combined with low doses of $1,25\text{-(OH)}_2\text{D}_3$, HL-60 leukemia cells were treated with various concentrations of synthetic compounds in combination with 5 nM of $1,25\text{-(OH)}_2\text{D}_3$, and the cellular differentiation was assessed by a nitroblue tetrazolium reduction assay. As shown in Fig. 1, the addition of the compounds **1**, **2a**, **3a**, and **5b** to cultures exposed to a

Table I. Effects of santonin derivatives on HL-60 cell differentiation. HL-60 cells were treated for 72 h with medium alone (M) or with 20 $\mu\text{g}/\text{mL}$ of santonin derivatives. The cell differentiation was assessed by the NBT assay. Each value represents the mean \pm s.e. mean ($n=3$).

Compound (20 $\mu\text{g}/\text{mL}$)	% Differentiated cells	
	Mean \pm s.e. mean	
M	3.0 \pm 1.5	
1	*30.9 \pm 2.8	
2a	9.3 \pm 2.0	
2b	2.1 \pm 0.3	
3a	10.6 \pm 1.6	
3b	ND ^a	
4a	5.6 \pm 0.6	
5b	17.3 \pm 1.8	

* $P < 0.001$, relative to an untreated group (M). ^aND, not detected.

suboptimal concentration of $1,25\text{-(OH)}_2\text{D}_3$ (5nM), which by itself caused a relatively low level of differentiation, resulted in a marked increase in the degree of cell differentiation, whereas the compounds **2b** and **4a** had no effects on leukemia cell differentiation. Especially, the compound **5b** significantly enhanced $1,25\text{-(OH)}_2\text{D}_3$ -induced cell differentiation. The compounds **2a**, **3a**, or **5b** synergistically enhanced $1,25\text{-(OH)}_2\text{D}_3$ -induced HL-60 cell differentiation, though the compounds themselves had little effect on HL-




Fig. 1. Effects of diacetoxy acetal analogues on 1,25-(OH)₂D₃-induced HL-60 cell differentiation. HL-60 cells were treated for 72 h with 5 nM 1,25-(OH)₂D₃ in combination with various concentrations (0-20 µg/mL) of compounds **1**, **2a**, **2b**, **3a**, **4a**, and **5b** (A). HL-60 cells were treated for 72 h with 5 nM 1,25-(OH)₂D₃ alone or in combination with various concentrations (0-100 µg/mL) of compound **1** (B) or **3a** (C). The cellular differentiation was assessed by the NBT assay. Each value represents the mean ± s.e.mean (n=3). **P*<0.05, relative to an untreated group. ***P*<0.05 relative to the 1,25-(OH)₂D₃ treated group.

60 cell differentiation. Moreover, as shown in Fig. 1B and C, despite of the similar potency of differentiation-inducing activity on 1,25-(OH)₂D₃-induced HL-60 cell differentiation with the compound **1**, and the compound **3a** did not affect the activity in HL-60 cell differentiation.

Many previous studies have shown some chemical combinations, which exert an additive or synergistic effect on HL-60 cell differentiation (Hershberger *et al.*, 2001; Kang *et al.*, 2001; Sokoloski *et al.*, 1997). Here, we reported the combined effects of the diacetoxy acetal derivatives of santonin with 1,25-(OH)₂D₃ affects on HL-60 cell differentiation. The compounds **1**, **2a**, **3a**, and **5b** potentiated the induction of HL-60 cell differentiation treated with 1,25-(OH)₂D₃, whereas the compounds **2b** and **4a** had no effects on leukemia cell differentiation. The compound **5b** is a most effective enhancer of HL-60 cell differentiation when combined with 1,25-(OH)₂D₃.

The mechanism by which the compound **5b** potentiates 1,25-(OH)₂D₃-induced HL-60 cell differentiation is not clear. However, the results presented here suggest that treatment of patients with combinations of **5b** and 1,25-(OH)₂D₃ may produce a greater therapeutic response than 1,25-(OH)₂D₃ alone, possibly with less toxicity. Clinical studies are needed to evaluate this possibility, especially at concentrations of the compound **5b** that do not have known side effects.

ACKNOWLEDGEMENT

This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (01-PJ10-PG6-01GN16-0005).

REFERENCES

- Ando, M., Wada, T., Kusaka, H., Takase, K., Hirata, N., and Yanagi, Y., Studies on the synthesis of sesquiterpene lactones 10. Improved synthesis of (+)-tuberiferin and the related alpha-methylene gamma-lactones and their biological activities. *J. Org. Chem.*, 52, 4782-4786 (1987).
- Beere, H. M. and Hickman, J. A., Differentiation: a suitable strategy for cancer chemotherapy. *Anti-Cancer Drug Design*, 8, 299-322 (1993).
- Breitman, T. R., Selonick, S. E., and Collins, S. J., Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. *Proc. Natl. Acad. Sci., U.S.A.*, 77, 2936-2940 (1980).
- Collins, S. J., Ruscetti, F. W., Gallagher, R. E., and Gallo, R. C., Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. *J. Exp. Med.*, 149, 969-974 (1979).
- Hall, I. H., Williams, W. L. Jr., Grippo, A. A., Lee, K. H.,

- Holbrook, D. J., and Chaney, S. G., Inhibition of nucleic acid synthesis in P-388 lymphocytic leukemia cells in culture by sesquiterpene lactones. *Anticancer Res.*, 8, 33-42 (1988).
- Hehner, S. P., Hofmann, T. G., Droge, W., and Schmitz, M. L., The antiinflammatory sesquiterpene lactone parthenolide inhibits NF- κ B by targeting the I κ B kinase complex. *J. Immunol.*, 163, 5617-5623 (1999).
- Hershberger, P. A., Yu, W. D., Modzelewski, R. A., Rueger, R. M., Johnson, C. S., and Trump, D. L., Calcitriol (1, 25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity *in vitro* and *in vivo* and accelerates paclitaxel-induced apoptosis. *Clin. Cancer Res.*, 7, 1043-1051 (2001).
- Kang, S. N., Lee, M. H., Kim, K. M., Cho, D., and Kim, T. S., Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C. *Biochem. Pharmacol.*, 61, 1487-1495 (2001).
- Kato, K., Hirata, Y., and Yamamura, S., Synthesis of shyobunone and related sesquiterpene. *Tetrahedron*, 27, 5987-92 (1971).
- Ohnishi, M., Yoshimi, N., Kawamori, T., Ino, N., Hirose, Y., Tanaka, T., Yamahara, J., Miyata, H., and Mori, H., Inhibitory effects of dietary protocatechuic acid and costunolide on 7,12-dimethylbenz[a]anthracene-induced hamster cheek pouch carcinogenesis. *Jpn. J. Cancer Res.*, 88, 111-119 (1997).
- Ross, J. J., Arnason, J. T., and Birnboim, H. C., Low concentrations of the feverfew component parthenolide inhibit *in vitro* growth of tumor lines in a cytostatic fashion. *Planta Med.*, 65, 126-129 (1999).
- Shibata, T., Okura, T., and Inayama, Dithioacetal; As a chiroptical Functional group to determine absolute and relative configurations by CD and 1H-NMR spectra. *Herocycle*, 24, 897-900 (1986).
- Simonvic, D. M., Rao, A. S., and Bhattacharyya, S. C., The synthesis of tetrahydro-sussurea lactone. *Tetrahedron*, 9, 1061-1071 (1963).
- Sokoloski, J. A., Shyam, K., and Sartorelli, A. C., Induction of the differentiation of HL-60 promyelocytic leukemia cells by curcumin in combination with low levels of vitamin D₃. *Oncol. Res.*, 9, 31-39 (1997).
- Studzinski, G. P. and Moore, D. C., Sunlight—can it prevent as well as cause cancer? *Cancer Res.*, 55, 4014-4022 (1995).
- Tanaka, H., Abe, E., Miyaura, C., Shiina, Y., and Suda, T., 1 α ,25-dihydroxyvitamin D₃ I nduces differentiation of human promyelocytic leukemia cells (HL-60) into monocytic macrophage, but not into granulocytes. *Biochem. Biophys. Res. Commun.*, 117, 86-92 (1983).